~~<i id='30A9B5364D'><strike id='30A9B5364D'><tt id='30A9B5364D'><pre id='30A9B5364D'></pre></tt></strike></i>~~

Home» comprehensive» comprehensive

comprehensive

author：explore 2025-10-04 10:36:50 Page View：78

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What's changing in Medicare's open enrollment this year?
Next article： Cancer drug shortages should be causing more outrage

knowledge

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

APStockChronickidneydiseasewasthestrongestriskfactorforsuddencardiacarrestamongHispanicandLatinoadul

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

AdobeHospitals,pharmacies,andotherhealthcareprovidersaregettingstuckinaninsuranceprocessinglogjamaft